TY - JOUR
T1 - Comparisons of clinical efficacy and safety between the brand- and generic-name fenofibrate in patients with hypertriglyceridemia
AU - Huang, Jen Hung
AU - Cheng, Ho Shun
AU - Chung, Cheng Chih
AU - Hsieh, Ming Hsiung
PY - 2013/8
Y1 - 2013/8
N2 - Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p
AB - Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p
KW - Brand-name drug
KW - Fibrate
KW - Generic-name drug
KW - Triglyceride
UR - http://www.scopus.com/inward/record.url?scp=84883459611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883459611&partnerID=8YFLogxK
U2 - 10.1016/j.jecm.2013.06.012
DO - 10.1016/j.jecm.2013.06.012
M3 - Article
AN - SCOPUS:84883459611
SN - 1878-3317
VL - 5
SP - 136
EP - 138
JO - Journal of Experimental and Clinical Medicine(Taiwan)
JF - Journal of Experimental and Clinical Medicine(Taiwan)
IS - 4
ER -